Cedrus Investments’ Chairman Mr. Rani Jarkas is Invited to Speak at the Hong Kong Biotech Invest and Partnering 2018

The Chairman of Cedrus Investments (“Cedrus”) Mr. Rani Jarkas is invited as the keynote speaker at the Asian Investment Series of the Hong Kong Biotech Invest & Partnering 2018 conference to be held on March 13, 2018, in Hong Kong. Cedrus has been participating and speaking at this annual event in Hong Kong, organized by AusBiotech (Australia’s biotechnology organization), since its inception in 2013 to foster investments in the life sciences industry across borders.

In recent years, the Asian Investment Series has expanded further to holding an annual conference in Shanghai, which is one of the hubs of life sciences investments in Asia. These conferences have brought together hundreds of Australian life sciences companies together with Hong Kong and Chinese life sciences investors where opportunities of cross-border collaborations are explored, for instance, to tap into the world’s second-largest biopharma market – China.

Mr. Jarkas will be sharing his extensive experience and profound insights, as well as Cedrus’ expertise in life sciences investment, and explaining why overseas life sciences companies should be using Hong Kong as the gateway for establishing their presence in Mainland China through joint ventures, licensing partnerships, strategic alliances or other initiatives onshore.

Mr. Jarkas said, “China is now committed to transforming the domestic life sciences industry into a global leader. For example, in recent years, we have seen growing interest from Chinese enterprises and investors to acquire life sciences technologies and products overseas to enhance China’s market position, and the increased desire of Australian life science companies to build a local presence in China. In this regard, Cedrus has competitive advantages. Through facilitating various deals, Cedrus has accumulated a lot of expertise and valuable experience in cross-border transactions and collaborations. We fully understand the potential sensitivity issues, apparent and hidden, involved in life sciences transactions across borders; hence, we can likely prevent companies from entering into unfavorable collaborations long term. In addition, we understand how to protect the companies’ assets such as intellectual properties, monetize their assets and maximize value, coupled with helping them to achieve their financial and business targets while minimizing business risks.”

About Cedrus Investments

Cedrus Investments is a global boutique investment firm that offers expertise in private wealth managementasset management and financial advisory services to a clientele of leading institutional investors, corporations, family offices and high net worth individuals around the world.

For further information about Cedrus Investments, please visit http://www.cedrusinvestments.com.

Media Enquiry:
Cedrus Investments Ltd.
Amy Sin
+852-3519-2828
information@cedrusinvestments.com

 

Source from:

http://www.cedrusinvestments.com/pdf/news/Cedrus%20Chairman%20Invited%20to%20Speak%20at%20the%20Hong%20Kong%20Biotech%20Invest%20&%20Partnering.pdf

 

 

Advertisements

NOVOGEN TO ESTABLISH CHINA ENTITY TO FURTHER COMMERCIALISATION AND PARTNERSHIPS IN WORLD’S SECOND-LARGEST PHARMACEUTICAL MARKET

NOVOGEN TO ESTABLISH CHINA ENTITY TO FURTHER COMMERCIALISATION AND PARTNERSHIPS IN WORLD’S SECOND-LARGEST PHARMACEUTICAL MARKET

Sydney, 13 November 2017 – Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology drug development company, announces today that it has entered into a Letter of Intent with Cedrus Investments Ltd for advisory services in order to establish a corporate structure focused on expansion into the Greater China region.
Key Points
• Following initial face-to-face discussions with third parties in China, Novogen has signed Letter of Intent with Cedrus Investments, a leading specialist investment bank based in Hong Kong, for advisory services in order to establish a corporate structure and operations in the People’s Republic of China
• Novogen entity will be a Wholly Foreign Owned Enterprise (WFOE), initially with minimal infrastructure, to serve as administrative unit for China expansion
• Key objective will be to further explore partnerships and commercialization opportunities in China over a medium- to long-term horizon
• China is the world’s second-largest pharmaceutical market, with approximately US$ 116.7 billion in annual sales, and an annual growth rate of 12.4% (per QuintilesIMS Market Prognosis, October 2016)
The new corporate entity will enable Novogen to interact directly with the Chinese Food and Drug Administration (CFDA) for future clinical trials of its pipeline in China, and will facilitate potential partnering and investing opportunities for the company.
The Letter of Intent defines the key terms of the proposed establishment, with most of the work expected to be conducted in the first half of calendar 2018, subject to execution of definitive agreements. It is expected that the Chinese entity will be a Wholly Foreign Owned Enterprise (WFOE), headquartered in Shanghai.
Novogen CEO, Dr James Garner, commented, “China is a key market for pharmaceutical companies, and over the last few months we have been actively exploring opportunities to engage with Chinese companies, researchers, and investors to support the development of Novogen’s current and future pipeline there. The team at Cedrus Investments have been helping global companies best position themselves to identify and work with investors and business partners in the Greater China region, and are highly experienced in navigating the complex regulatory requirements in China. We are pleased to be working with them on this important project. The new corporate structure will put us in a stronger position to capitalize on opportunities in China over the medium term.”
In addition to its Australian operations and the intended China operation, Novogen also has a US-based corporate entity, Novogen North America, Inc.

RANI JARKAS – Development of Clean Technology

The significance of a clean economy

Clean technology is based on the principles of biology, resource efficiency and second generation concept in basic industries.

The concept of clean technology refers to any process, product or service that helps to improve energy efficiency, sustainable use of resources or active environmental protection. This technology is very widespread, it is related to recycling, renewable energy, green transport, green chemistry and much more.

The clean technology is oriented to the transfer of energy sources from coal or other fossil fuels to solar power sources or hydroelectric power plants. It can be said that clean technology projects are actually renewable energy projects with good predispositions for future widespread use. Also, the goal is to reduce the total carbon emissions in the air so that the environment would be cleaner.

Rani Jarkas, who has a successful experience in the field of life sciences, points out that it is important to invest in clean technology, in order to achieve a better quality of life for all living beings on the planet.

Source: https://rani-jarkas.blogspot.com/2018/01/rani-jarkas-development-of-clean.html

 

 

 

CEDRUS INVESTMENTS HOSTED LIFE SCIENCES LUNCHEON IN SHANGHAI, 13TH NOVEMBER 2017

SHANGHAI, 14th November 2017 – Cedrus Investments (“Cedrus”), a global boutique
investment firm, hosted the second meeting of the life sciences luncheon series for this year on Monday, 13th November 2017 in Shanghai at the St. Regis Shanghai Jingan. Mr. Randy Hice, Cedrus’ Chief Technical Officer and Member of the Life Sciences Advisory Board, shared with institutional investors, venture capitalists, and company executives his insights on two crucial themes in biotechnology: “New Frontiers in Immunology R&D” and “Increasing Laboratory Productivity and Meeting FDA Compliance through Software”.
Mr. Hice is recognized globally as a leading authority in laboratory informatics and the most published author in the world on topics of complex laboratory automation and workflow analysis. His recent positions included the CEO of Laboratory Expertise Center, Inc. and Manager of Global Strategy at Abbott Informatics, a division of Abbott Laboratories.

 

The event was well received, and elicited high-level discussion in the Q&A session following Mr. Hice’s speech. Investors thought that it was especially important to understand the very latest developments in the biotech industry, as well as the overseas regulatory environment in order to conform to international conventions. Those attended the luncheon included executives from Fountainvest Partners, Franklin Templeton Sealand, Qiming VC, and SAIF Partners.
Cedrus’ Chief Technical Officer, Mr. Randy Hice said, “I am glad to be able to share the
latest trends in immunology research and development with investors and companies, as well as providing some perspectives on how progressive scientific enterprises are utilizing the latest tools available to improve their data quality while achieving FDA compliance. The feedback from the event’s participants provided us with a better understanding of the active areas of interest from Chinese life sciences investors and companies, and that understanding will no doubt facilitate future cooperation regarding cross-border transactions and investment opportunities.”
Cedrus’ Chairman, Mr. Rani Jarkas said, “With its particular focus on the Greater China region, Cedrus has always positioned itself as a leader in fulfilling the needs of the investment community and companies around the world. Given our global network and expertise in the life sciences industry, we can serve as the platform for both investors and companies worldwide, facilitating both inbound and outbound investments for the Chinese and other geographical markets.”

 

#RaniJarkas, #CedrusInvestments

 

Rani Jarkas: Hong Kong will continue to be a competitive center of international finance

Chinese President Xi Jinping has arrived in Hong Kong to embark on a three-day trip to attend a ceremony marking the 20th anniversary of Hong Kong’s return to China. Xi also will attend the inauguration of the fifth administration of the Hong Kong Special Administrative Region.

“President Xi’s visit to the SAR at this important moment to attend the celebration activities and the inauguration ceremony fully shows the importance that the central authorities attach to and their support for Hong Kong,” Leung Chun-ying, chief executive of Hong Kong, said.

With China continuously strengthening itself on the global economic and political stage, Zhang Xiaoming, the SAR Liaison Office director, commented Hong Kong will benefit from the country’s three major development initiatives: the Belt and Road Initiative, the internationalization of the renminbi, and the building of the Guangdong-Hong Kong-Macao Greater Bay Area.

Rani Jarkas, Chairman of Cedrus Investments, a global boutique investment firm headquartered in Hong Kong, said, “Over the past 20 years, with the support of the central government, Hong Kong SAR has made progress in various areas. Hong Kong has remained and will continue to be a center of international finance, shipping and trade, and has been recognized as the world’s freest economy and most competitive region.”

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. – Rani Jarkas

王雷(Rani Jarkas):香港仍将是极具竞争力的全球金融中心

中国国家主席习近平今天抵达香港进行为期三天的行程,期间将出席庆祝香港回归祖国20周年大会暨香港特别行政区第五届政府就职典礼。

“习主席在这个重大时刻莅临出席庆祝活动和就职典礼,并视察香港特别行政区,充分显示中央对香港的重视和支持,”香港特区行政长官梁振英说。

随着中国持续增强其在全球政治经济舞台上的重要性,中央政府驻香港联络办公室主任张晓明评论道:“现在国家有三大发展战略都和香港密切相关,即“一带一路”建设、人民币国际化粤港澳大湾区城市群规划和建设。

总部位于香港的全球精品投资公司——赛德思投资董事长王雷表示:“20年来,香港特别行政区在国家的大力支持下,取得多方面的成就。香港保持了并仍将保持是全球金融、货运和贸易中心之一,并且一直被评选为全球最自由经济体以及最具竞争力地区之一。”

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. – Rani Jarkas

Rani Jarkas: The Belt and Road Initiative: The Biggest Economic Cooperation Project Today

In mid-May, Chinese President Xi Jinping welcomed the world leaders attending the Belt and Road Forum (BRF) for International Cooperation in Beijing. The forum is a major boost and accelerator for synergies along the roads.

International Monetary Fund Managing Director Christine Lagarde commented on the BRF that “The Belt and Road Initiative is about connecting cultures, communities, economies, and people, and about adding new economic flavors by creating infrastructure projects that are based on 21st-century expertise and governance standards.”

The Belt and Road Initiative is a pioneering, international framework based on an “open platform concept,” which does not need a leader, but a curator who acts as a catalyst and coordinator for ensuring win-win outcomes, said Klaus Schwab, founder and executive chairman of the World Economic Forum.

Rani Jarkas, Chairman of Cedrus Investments, an experienced investor in the region under Belt and Road Initiative, said, “The Belt and Road Initiative is meant to help developing countries to create more opportunities for growth and improve the lives of people. The breadth of this initiative, the high level of participation and its strategic dimensions, highlight its capacity to become the biggest economic cooperation project in place in this century.”

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. – Rani Jarkas